Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Agonist Antibody

BACKGROUND: Resistance of tumors to cell death signals poses a complex clinical problem. We explored the therapeutic potential and in vivo toxicity of a combination of bortezomib, a proteasome inhibitor, and MD5-1, a tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptor (DR5) agon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shanker, Anil, Brooks, Alan David, Tristan, Carlos Alberto, Wine, John William, Elliott, Peter John, Yagita, Hideo, Takeda, Kazuyoshi, Smyth, Mark John, Murphy, William Joseph, Sayers, Thomas Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2753966/
https://ncbi.nlm.nih.gov/pubmed/18445820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djn113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados